Century Therapeutics, Inc. Interest Expense on Debt
Century Therapeutics, Inc. (IPSC) reported Interest Expense on Debt of $540.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2025-03-19
- Century Therapeutics, Inc. interest expense, debt for the quarter ending 2023-12-31 was $0.00.
- Century Therapeutics, Inc. interest expense, debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. interest expense, debt for the quarter ending 2023-06-30 was $136.00K, a 46.46% decline year-over-year.
- Century Therapeutics, Inc. interest expense, debt for the quarter ending 2023-03-31 was $348.00K, a 46.22% increase year-over-year.
- Century Therapeutics, Inc. interest expense, debt for fiscal 2023 was $540.00K, a 31.39% decline from fiscal 2022.
- Century Therapeutics, Inc. interest expense, debt for fiscal 2022 was $787.00K, a 18.78% decline from fiscal 2021.
- Century Therapeutics, Inc. interest expense, debt for fiscal 2021 was $969.00K, a 235.29% increase from fiscal 2020.
- Century Therapeutics, Inc. interest expense, debt for fiscal 2020 was $289.00K.
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 9 month | Interest Expense, Debt 12 month | Interest Expense, Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $0.00 derived: sum of 2 quarters · filed 2025-03-19 | $136.00K derived: sum of 3 quarters · filed 2025-03-19 | $540.00K 10-K · filed 2025-03-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $136.00K derived: sum of 2 quarters · filed 2024-11-05 | $540.00K 10-Q · filed 2024-11-05 | $484.00K derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $136.00K 10-Q · filed 2023-08-09 | $540.00K 10-Q · filed 2024-08-08 | $484.00K derived: sum of 3 quarters · filed 2024-05-09 | $780.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2023-03-31 | $348.00K 10-Q · filed 2024-05-09 | $348.00K derived: sum of 2 quarters · filed 2024-05-09 | $644.00K derived: sum of 3 quarters · filed 2024-05-09 | $898.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $296.00K derived: sum of 2 quarters · filed 2024-03-14 | $550.00K derived: sum of 3 quarters · filed 2024-03-14 | $787.00K 10-K · filed 2024-03-14 | $1.10M 10-K · filed 2023-03-16 |
| 2022-09-30 | $296.00K 10-Q · filed 2023-11-09 | $550.00K derived: sum of 2 quarters · filed 2023-11-09 | $787.00K 10-Q · filed 2023-11-09 | $1.03M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $254.00K 10-Q · filed 2023-08-09 | $492.00K 10-Q · filed 2023-08-09 | $736.00K derived: sum of 3 quarters · filed 2023-08-09 | $981.00K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $238.00K 10-Q · filed 2023-05-11 | $482.00K derived: sum of 2 quarters · filed 2023-05-11 | $727.00K derived: sum of 3 quarters · filed 2023-05-11 | $969.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $489.00K derived: sum of 2 quarters · filed 2023-03-16 | $731.00K derived: sum of 3 quarters · filed 2023-03-16 | $969.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $245.00K 10-Q · filed 2022-11-10 | $487.00K derived: sum of 2 quarters · filed 2022-11-10 | $725.00K 10-Q · filed 2022-11-10 | $970.00K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $242.00K 10-Q · filed 2022-08-11 | $480.00K 10-Q · filed 2022-08-11 | $725.00K derived: sum of 3 quarters · filed 2022-08-11 | $770.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $239.00K 10-Q · filed 2022-05-16 | $483.00K derived: sum of 2 quarters · filed 2022-05-16 | $528.00K derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $289.00K derived: sum of 2 quarters · filed 2022-03-17 | $289.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $45.00K 10-Q · filed 2021-11-10 | $45.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |